Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Nimodipine
Therapeutic Area : Neurology
Study Phase : Phase I/ Phase II
Sponsor : Acasti Pharma
Deal Size : $64.0 million
Deal Type : Acquisition
Acasti Announces Definitive Agreement to Acquire Grace Therapeutics, Inc.
Details : Grace provides Acasti with a pipeline of rare and orphan disease programs. Grace's GTX-104 is a Novel aqueous nanoparticle formulation of water insoluble nimodipine, is believed to potentially improve the management of hypotension and vasospasm in SAH pa...
Brand Name : GTX-104
Molecule Type : Small molecule
Upfront Cash : $64.0 million
May 07, 2021
Lead Product(s) : Nimodipine
Therapeutic Area : Neurology
Highest Development Status : Phase I/ Phase II
Sponsor : Acasti Pharma
Deal Size : $64.0 million
Deal Type : Acquisition
LOOKING FOR A SUPPLIER?